Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | TPMT | P51580 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30506535 | 1.00 | HCAR1 (0.55) | HCAR1HCAR2CES2CES1L3MBTL1 | |
| SCHEMBL22400317 | 0.93 | HCAR1 (0.48) | HCAR1HCAR2CES2CES1L3MBTL1 | |
| SCHEMBL918608 | 0.84 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6733033 | 0.84 | CA1 (0.46) | HCAR1CA12CA1CA2CA7 | |
| SCHEMBL5151998 | 0.82 | CES2 (0.41) | HCAR1HCAR2CES2CES1 | |
| SCHEMBL29821986 | 0.82 | PARP1 (0.52) | HCAR1HCAR2CES2CES1 | |
| SCHEMBL14120715 | 0.82 | PARP1 (0.52) | HCAR1HCAR2CES2CES1 | |
| SCHEMBL28959114 | 0.80 | APP (0.46) | HCAR1PPARA | |
| SCHEMBL157714 | 0.79 | HCAR1 (0.73) | HCAR1HCAR2CES2CES1L3MBTL1 | |
| SCHEMBL336433 | 0.79 | HCAR1 (0.73) | HCAR1HCAR2CES2CES1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111146496-B | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池股份有限公司 | 2021-07-13 | — | — | CN | claimed |
| CN-112679535-A | Small molecule PAD4 inhibitor and preparation method and application thereof | 首都医科大学 | 2021-04-20 | — | — | CN | claimed |
| CN-111162313-A | Polymer electrolyte and lithium ion battery | 珠海冠宇电池有限公司 | 2020-05-15 | — | — | CN | claimed |
| CN-111146496-A | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池有限公司 | 2020-05-12 | — | — | CN | claimed |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4323354-B1 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | NOVARTIS AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-06-05 | — | — | US | disclosed |
| CN-120058751-A | Pleuromutilin derivative with arylboronic acid or arylboronic acid ester fragment, and preparation method and application thereof | 中国医学科学院药物研究所 | 2025-05-30 | — | — | CN | disclosed |
| CN-119192845-B | Preparation method of high-temperature-resistant high-heat-conductivity PPS composite material | 东莞市普万光电散热科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-118772595-B | Wear-resistant glass fiber reinforced plastic well lid containing polyester and preparation method thereof | 山东金光复合材料股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-118772595-A | Wear-resistant glass fiber reinforced plastic well lid containing polyester and preparation method thereof | 山东金光复合材料股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240182456-A1 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-30 | — | — | US | disclosed |
| EP-2855489-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2507236-B1 | Triazolopyridine derivates | BAYER IP GMBH (DE) | 2014-12-17 | — | — | EP | disclosed |
| WO-2014159559-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159559-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013163241-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| EP-2507236-A1 | TRIAZOLOPYRIDINE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011064328-A1 | TRIAZOLOPYRIDINE DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | HCAR1 137/4885HCAR2 96/4885CES2 2588/4885 |
| US-20240182456-A1 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | GLP1R, GPR119, IRS1 | HCAR1 964/4885HCAR2 627/4885CES2 1090/4885 |
| US-20150119390-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, F2RL1 | HCAR1 351/4885HCAR2 495/4885CES2 2777/4885 |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | HCAR1 338/4885HCAR2 167/4885CES2 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.